Standard
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection : a randomised, double-blind, phase 3, non-inferiority trial. / DeJesus, Edwin; Rockstroh, Jürgen K; Henry, Keith; Molina, Jean-Michel; Gathe, Joseph; Ramanathan, Srinivasan; Wei, Xuelian; Yale, Kitty; Szwarcberg, Javier; White, Kirsten; Cheng, Andrew K; Kearney, Brian P; GS-236-0103 Study Team ; Gerstoft, Jan.
In:
Lancet, Vol. 379, No. 9835, 2012, p. 2429-38.
Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
DeJesus, E, Rockstroh, JK, Henry, K, Molina, J-M, Gathe, J, Ramanathan, S, Wei, X, Yale, K, Szwarcberg, J, White, K, Cheng, AK, Kearney, BP, GS-236-0103 Study Team
& Gerstoft, J 2012, '
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial',
Lancet, vol. 379, no. 9835, pp. 2429-38.
https://doi.org/10.1016/S0140-6736(12)60918-0APA
DeJesus, E., Rockstroh, J. K., Henry, K., Molina, J-M., Gathe, J., Ramanathan, S., Wei, X., Yale, K., Szwarcberg, J., White, K., Cheng, A. K., Kearney, B. P., GS-236-0103 Study Team
, & Gerstoft, J. (2012).
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial.
Lancet,
379(9835), 2429-38.
https://doi.org/10.1016/S0140-6736(12)60918-0Vancouver
DeJesus E, Rockstroh JK, Henry K, Molina J-M, Gathe J, Ramanathan S et al.
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial.
Lancet. 2012;379(9835):2429-38.
https://doi.org/10.1016/S0140-6736(12)60918-0Author
DeJesus, Edwin ; Rockstroh, Jürgen K ; Henry, Keith ; Molina, Jean-Michel ; Gathe, Joseph ; Ramanathan, Srinivasan ; Wei, Xuelian ; Yale, Kitty ; Szwarcberg, Javier ; White, Kirsten ; Cheng, Andrew K ; Kearney, Brian P ; GS-236-0103 Study Team ; Gerstoft, Jan. / Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection : a randomised, double-blind, phase 3, non-inferiority trial. In: Lancet. 2012 ; Vol. 379, No. 9835. pp. 2429-38.
Bibtex
@article{e4cc4d3f19cd4b17a6c3f09e5bb485e2,
title = "Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial",
abstract = "The HIV integrase strand transfer inhibitor elvitegravir (EVG) has been co-formulated with the CYP3A4 inhibitor cobicistat (COBI), emtricitabine (FTC), and tenofovir disoproxil fumarate (TDF) into a once-daily, single tablet. We compared EVG/COBI/FTC/TDF with a ritonavir-boosted (RTV) protease inhibitor regimen of atazanavir (ATV)/RTV+FTC/TDF as initial therapy for HIV-1 infection.",
author = "Edwin DeJesus and Rockstroh, {J{\"u}rgen K} and Keith Henry and Jean-Michel Molina and Joseph Gathe and Srinivasan Ramanathan and Xuelian Wei and Kitty Yale and Javier Szwarcberg and Kirsten White and Cheng, {Andrew K} and Kearney, {Brian P} and Jan Gerstoft and Jan Gerstoft",
note = "Copyright {\textcopyright} 2012 Elsevier Ltd. All rights reserved.",
year = "2012",
doi = "10.1016/S0140-6736(12)60918-0",
language = "English",
volume = "379",
pages = "2429--38",
journal = "The Lancet",
issn = "0140-6736",
publisher = "TheLancet Publishing Group",
number = "9835",
}
RIS
TY - JOUR
T1 - Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection
T2 - a randomised, double-blind, phase 3, non-inferiority trial
AU - DeJesus, Edwin
AU - Rockstroh, Jürgen K
AU - Henry, Keith
AU - Molina, Jean-Michel
AU - Gathe, Joseph
AU - Ramanathan, Srinivasan
AU - Wei, Xuelian
AU - Yale, Kitty
AU - Szwarcberg, Javier
AU - White, Kirsten
AU - Cheng, Andrew K
AU - Kearney, Brian P
AU - GS-236-0103 Study Team
AU - Gerstoft, Jan
N1 - Copyright © 2012 Elsevier Ltd. All rights reserved.
PY - 2012
Y1 - 2012
N2 - The HIV integrase strand transfer inhibitor elvitegravir (EVG) has been co-formulated with the CYP3A4 inhibitor cobicistat (COBI), emtricitabine (FTC), and tenofovir disoproxil fumarate (TDF) into a once-daily, single tablet. We compared EVG/COBI/FTC/TDF with a ritonavir-boosted (RTV) protease inhibitor regimen of atazanavir (ATV)/RTV+FTC/TDF as initial therapy for HIV-1 infection.
AB - The HIV integrase strand transfer inhibitor elvitegravir (EVG) has been co-formulated with the CYP3A4 inhibitor cobicistat (COBI), emtricitabine (FTC), and tenofovir disoproxil fumarate (TDF) into a once-daily, single tablet. We compared EVG/COBI/FTC/TDF with a ritonavir-boosted (RTV) protease inhibitor regimen of atazanavir (ATV)/RTV+FTC/TDF as initial therapy for HIV-1 infection.
U2 - 10.1016/S0140-6736(12)60918-0
DO - 10.1016/S0140-6736(12)60918-0
M3 - Journal article
VL - 379
SP - 2429
EP - 2438
JO - The Lancet
JF - The Lancet
SN - 0140-6736
IS - 9835
ER -
